Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Assets (2024 - 2025)

Prelude Therapeutics' Current Assets history spans 2 years, with the latest figure at $105.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 22.23% year-over-year to $105.7 million; the TTM value through Dec 2025 reached $105.7 million, down 22.23%, while the annual FY2025 figure was $105.7 million, 22.23% down from the prior year.
  • Current Assets for Q4 2025 was $105.7 million at Prelude Therapeutics, up from $58.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $205.4 million in Q1 2024 and bottomed at $58.3 million in Q3 2025.